CryoLife, Inc. Declares A 3-For-2 Stock Split

ATLANTA, Nov. 27 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer of stentless heart valves and surgical adhesives, announced that its Board of Directors has authorized a 3-for-2 stock split, to be effected as a stock dividend, to shareholders of record on December 8, 2000. New share certificates will be mailed to shareholders on December 27, 2000. Fractional shares will be aggregated and sold, with the proceeds distributed to shareholders in lieu of the issuance of such shares. CryoLife, Inc. had approximately 12,500,000 common shares outstanding as of November 27, 2000.

Steven G. Anderson, President and Chief Executive Officer, CryoLife, Inc. noted, "The action of the Board of Directors follows the recent increase in the Company's share price and provides an opportunity to increase the liquidity of the Company. The availability of additional shares should also enable future investors to trade more actively in the company's stock".

Founded in 1984, CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is approved as an adjunct in the repair of acute thoracic aortic dissections under HDE regulations in the United States and is CE marked in the European Union and approved in Canada for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft(R) heart valve, the world's first tissue-engineered heart valve replacement and the CryoLife-O'Brien(R) and CryoLife-Ross(R) stentless porcine heart valves, which are CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's web site: http://www.cryolife.com .

SOURCE CryoLife, Inc.

CONTACT: Roy Vogeltanz, Vice President, Corporate Communications, of CryoLife, Inc., 800-438-8285/